Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder

Next Previous
Trial Profile

Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Eribulin (Primary) ; Gemcitabine (Primary)
  • Indications Bladder cancer; Urethral cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Jan 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.
    • 04 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top